The purpose of this study is to investigate the safety, tolerability and anti-tumor effects of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with castrate metastatic prostate cancer.

Condition	Intervention	Phase
Prostatic Neoplasms	Drug: Samarium Sm-153 lexidronam + Docetaxel	Phase I Phase II

Further Study Details: 

Expected Total Enrollment:  69

The principal objective of this trial is to evaluate the safety, feasibility, and anti-tumor effects of a novel bone-targeted regimen consisting of Samarium Sm-153 lexidronam combined with docetaxel and prednisone. This present study design permits evaluation of the clinical activity of combining two distinct agents that have shown benefit for the treatment of patients with advanced androgen-independent prostate cancer and bone metastases. It enables assessment of potential synergistic interactions between a cytotoxic chemotherapy agent and a bone-targeting radioisotope agent in the setting of a bone-targeted therapy.

Genders Eligible for Study:  Male

Criteria

Inclusion Criteria:

• Have histological evidence of adenocarcinoma of the prostate.
• Have progressive castrate metastatic disease.
• Castrate levels of testosterone (<50 ng/ml). Treatment to maintain castrate levels of testosterone must be continued.
• Must have evidence of at least 3 bone metastases on bone scan.
• Patients for whom initial hormone treatment (exclusive of neoadjuvant hormone therapy) was a combined androgen blockade approach, must show progression of disease following withdrawal of the anti-androgen prior to enrollment.
• Patients undergoing prior bisphosphonate treatments are eligible.
• Patients who have received one prior treatment with 153Sm lexidronam or 89Sr are eligible provided it is at least 12 weeks from treatment with 153Sm lexidronam or 24 weeks from treatment with 89Sr.
• Life expectancy of at least 12 weeks (based on co-morbidity).
• KPS>60.
• Lab requirements: *White Blood Count (WBC) ≥ 3,000/mm3; *Absolute Neutrophil Count (ANC) ≥ 1,500/ mm3; *Platelet (PLT) ≥ 100,000/mm3; *Hemoglobin (HGB) ≥ 10 mg/dl; *Bilirubin ≤ 2.0 mg/dl; *ALT/AST≤ 3 times the upper limit of normal; *Serum creatinine ≤ 2.0 mg/dl.
• Patients must sign an informed consent.

Exclusion Criteria:

• Patients with small cell carcinoma.
• Patients with predominant visceral metastases (>3 lung or liver lesions) or symptomatic lymphadenopathy (scrotal or pedal edema).
• Patients who have received more than one course of external beam radiation therapy directed at bone lesions.
• Clinically significant cardiac disease (New York Heart Association Class III/IV).
• History of other malignancies (other than non-melanoma skin cancer), unless in complete remission or off therapy for that disease for at least five years.
• Have or are participating in a research study protocol or clinical trial protocol within 30 days of the date of the baseline visit.

Please refer to this study by ClinicalTrials.gov identifier  NCT00121095

Karen Dwyer      800-833-3533  Ext. 8272    kdwyer@cytogen.com

New York
      Memorial Sloan-Kettering Cancer Center, New York,  New York,  10021,  United States; Recruiting

Study chairs or principal investigators

Michael J Morris, M.D.,  Principal Investigator,  Memorial Sloan-Kettering Cancer Center   

Study ID Numbers:  424Sm32
Record last reviewed:  July 2005
Last Updated:  July 25, 2005
Record first received:  July 20, 2005
ClinicalTrials.gov Identifier:  NCT00121095
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-07-26